Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

SJB2-043

  Cat. No.:  DC30019   Featured
Chemical Structure
63388-44-3
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
SJB2-043 is an inhibitor of the native USP1/UAF1 complex with IC50 of 544 nM.SJB2-043 causes a dose-dependent decrease in ubiquitin-specific protease 1 (USP1) levels and a concomitant degradation of inhibitor of DNA-binding-1 (ID1) protein in the K562 cells at a micromolar drug concentration. SJB2-043 also causes a decrease in the levels of other ID proteins, namely ID2 and ID3 in K562 cells. SJB2-043 causes a dose-dependent decrease in the number of viable K562 cells, with an EC50 of approximately 1.07 μM. Moreover, SJB2-043 induces apoptosis of K562 cells in a dose-dependent manner.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 63388-44-3
Chemical Name: SJB2-043
Synonyms: SJB2-043;2-phenylbenzo[f][1,3]benzoxazole-4,9-dione;2-PHENYLNAPHTHO[2,3-D]OXAZOLE-4,9-DIONE;C17H9NO3;SJB2 043;BCP11060;2-phenyl-naphthoxazole-4,9-quinone;4047AH;BDBM50069763;FD5016;AK205527;AB0087822;2-phenyl-naphtho[2,3-d]oxazole-4,9-dione;Naphth[2,3-d]oxazole-4,9-dione, 2-phenyl-;2-Phenyl-4,9-dihydronaphtho[2,3-d]oxazole-4,9-dione;2-Phenyl-naphth[2,3-d]oxazole-4,9-dione;A917582;sjb2-043;sjb2-043;sjb2-043;2-Phenyl?-naphth[2,?3-?d]?oxazole-?4,?9-?dione;2-Phenyl?-naphth[2,?3-?d]?oxazole-?4,?9-?dione;2-Phenyl?-naphth[2,?3-?d]?oxazole-?4,?9-?dione;HY-15757;HY-15757;HY-15757;2-PHENYLNAPHTHO[2,3-D][1,3]OXAZOLE-4,9-DIONE;2-PHENYLNAPHTHO[2,3-D][1,3]OXAZOLE-4,9-DIONE;2-PHENYLNAPHTHO[2,3-D][1,3]OXAZOLE-4,9-DIONE;CS-1650;CS-1650;CS-1650;DTXSID40333501;DTXSID40333501;DTXSID40333501;SCHEMBL7808226;SCHEMBL7808226;63388-44-3;63388-44-3;EX-A3261;EX-A3261;AC-36369;AC-36369;AKOS027254768;AKOS027254768;BS-17354;BS-17354;GLXC-04102;GLXC-04102;GTPL12225;GTPL12225;CHEMBL3407552;CHEMBL3407552;MFCD26960957;MFCD26960957;SJB2043;SJB2043;SCHEMBL7808226;63388-44-3;EX-A3261;AC-36369;AKOS027254768;BS-17354;GLXC-04102;GTPL12225;CHEMBL3407552;sjb2-043;MFCD26960957;2-Phenyl?-naphth[2,?3-?d]?oxazole-?4,?9-?dione;SJB2043;HY-15757;2-PHENYLNAPHTHO[2,3-D][1,3]OXAZOLE-4,9-DIONE;CS-1650;DTXSID40333501;SCHEMBL7808226;63388-44-3;EX-A3261;AC-36369;AKOS027254768;BS-17354;GLXC-04102;GTPL12225;CHEMBL3407552;MFCD26960957;SJB2043
SMILES: O1C(C2C([H])=C([H])C([H])=C([H])C=2[H])=NC2C(C3=C([H])C([H])=C([H])C([H])=C3C(C1=2)=O)=O
Formula: C17H9NO3
M.Wt: 275.2583
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: SJB2-043 is an inhibitor of the native USP1/UAF1 complex with IC50 of 544 nM.
Target: IC50: 544 nM (USP1/UAF1)[1]
In Vitro: SJB2-043 causes a dose-dependent decrease in ubiquitin-specific protease 1 (USP1) levels and a concomitant degradation of inhibitor of DNA-binding-1 (ID1) protein in the K562 cells at a micromolar drug concentration. SJB2-043 also causes a decrease in the levels of other ID proteins, namely ID2 and ID3 in K562 cells. SJB2-043 causes a dose-dependent decrease in the number of viable K562 cells, with an EC50 of approximately 1.07 μM. Moreover, SJB2-043 induces apoptosis of K562 cells in a dose-dependent manner[1].
Kinase Assay: The in vitro enzymatic assays are performed using ubiquitin-AMC (Ub-7-amido-4methylcoumarin) as a substrate in a reaction buffer containing 20 mM HEPES-KOH (pH 7.8), 20 mM NaCl, 0.1 mg/mL ovalbumin, 0.5 mM EDTA and 10 mM dithiothreitol. The fluorescence is measured by FluoStar Galaxy Fluorometer. For the Ub-vinylsulfone (VS) assay, the proteins are incubated with Ub-VS at 0.5 μM final concentration for 45 min at 30°C, followed by the immunoblotting analysis[1].
Cell Assay: Leukemic cell lines are grown in RPMI 1640 medium supplemented with 10% fetal bovine serum and penicillin/streptomycin. Hela cells and U2OS cells are grown in DMEM supplemented with 10% fetal bovine serum and penicillin/streptomycin. USP1 inhibitor C527 and its derivatives (e.g., SJB2-043) are synthesized and the purity is validated by high-performance liquid chromatography. Primary human AML patient samples are collected from DFCI leukemia program under the approval of appropriate protocols. Cells are treated with DMSO or USP1 inhibitors (e.g., SJB2-043) in appropriate medium for 24-72 hrs. The viable cell counts are determined using Trypan blue staining, Cell TiterGlo reagent or MTT assay. The apoptotic cells are detected using AnnexinV and 7AAD staining using flow cytometry. For Benzidine staining, the cells are washed twice with PBS and resuspended in 45 μL of PBS + 5 μL of Benzidine stain solution (0.2% in 0.5 M glacial acetic acid, 3% H2O2). After 45 min incubation at room temperature, the Benzidine positive cells are detected by light microscopy[1].
References: [1]. Mistry H, et al. Small molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol Cancer Ther. 2013 Dec;12(12):2651-62.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC60859 MT-125(MT 125) MT125​​ is a brain-penetrant small-molecule inhibitor selectively targeting non-muscle myosin IIA/B (NMIIA/B) with >20-fold specificity over cardiac myosin. It demonstrates potent anti-glioblastoma activity by: (1) blocking tumor invasion and cytokinesis (inducing polyploidy), (2) disrupting mitochondrial dynamics to elevate ROS and trigger ferroptosis, and (3) sensitizing tumors to radiotherapy/kinase inhibitors via ROS-driven PDGFR/mTOR pathway activation. Subcutaneous administration achieves brain concentrations twice plasma levels (t1/2~10.5 hr) with no toxicity observed at 15× the therapeutic dose in rats. MT-125 monotherapy extends survival in GBM models, while combinations with PDGFR/PI3K inhibitors induce long-term remission (>40% mice). Its first-in-class mechanism, safety profile, and CNS bioavailability support clinical development for glioblastoma.
DC60781 TRPC6 activator compound 2 TRPC6 activator compound 2 is selective activator of TRPC6 that does not potentiate TRPC3 and mTRPC7. Comp2 is able to cross BBB.
DC66546 R-Sirpiglenastat R-Sirpiglenastat is the R- isomer of Sirpiglenastat(DRP-104).Sirpiglenastat (DRP104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response.
DC60597 AZD0780 AZD0780 is the first oral small molecule PCSK9 inhibitor for the treatment of hypercholesterolemia.
DC90056 PLX-5622 HCl form (water solubility form) PLX5622 is the HCl salt form of PLX-5622, which has better water solubility.PLX-5622 is a highly selective brain-penetrant CSF1R inhibitor (IC50=0.016 µM; Ki=5.9 nM) allowing for extended and specific microglial elimination, preceding and during pathology development.
DC65830 1-M-PES(1-Methoxy-5-methylphenazinium ethyl sulfate) 1-m-PES is an electron mediator which has higher stability of solutions than 1-Methoxy PMS. The stability in neutral to alkali conditions has been extremely improved with 1-Methoxy PES. 1-M-PES is a stable small-molecular compound and it has an equal or higher thermal stability than diaphorase. The 1-Methoxy PES solution can be stored long term.
DC65821 Upadacitinib hemihydrate Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC50 of 43 nM, being developed for the treatment of several autoimmune disorders.
DC65697 HDAC6 inhibitor 4510 A novel and seletive HDAC6 inhibitor.
DC65676 Fenretinide Glucuronide Monosodium Salt Fenretinide Glucuronide Monosodium Salt, is the metabolite of Fenretinide (F250000), which is a synthetic retinoid deriverative, substances related to vitamin A. They are also shown to be used for the treatment of cancer, as well as in the treatment of cystic fibrosis, rheumatoid arthritis, acne, and psoriasis.
DC89083 Pacritinib citrate Pacritinib Citrate is the citrate salt form of pacritinib, an orally bioavailable inhibitor of Janus kinase 2 (JAK2).
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia